about us


We are focused on the clinical development of novel therapies for cancer. Our programs include a potential best-in-class HDAC inhibitor, Pracinostat, and isoflavone-based compounds ME-143 and ME-344.
[ Read more ]

latest news

MEI Pharma Initiates Phase II Clinical Trial of Pracinostat and Vidaza in Frontline Myelodysplastic Syndrome
[ June 18, 2013 ]

MEI Pharma Adds Former YM BioSciences CEO Nick Glover to Board of Directors
[ June 11, 2013 ]

MEI Pharma's Mitochondrial Inhibitor Drug Candidate ME-344 Delays Tumor Growth in Recurrent Ovarian Cancer Model
[ April 10, 2013 ] [ Poster ]

Marshall Edwards Announces Name Change to MEI Pharma (“MEIP”)
Click here for our 2012 Annual Report